Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This pilot observational study evaluates the feasibility and acceptability of conducting a prospective study alongside the individualized integrative oncology cure stay program "Via Shalva" for breast and gynecological cancer survivors. The study further explores preliminary changes in patient-reported outcomes, physiological measures, and biological markers before and after the retreat and compared with a matched control group.
Breast and gynecological cancer survivors frequently experience long-term physical and psychological symptoms after completing primary treatment, including fatigue, anxiety, stress, sleep disturbances, and reduced quality of life. Integrative oncology approaches-such as acupuncture, yoga, mindfulness, psycho-oncological support, and individualized lifestyle counselling-may help alleviate these symptoms, but evidence from structured, prospective research remains limited. "Via Shalva," a 7-day integrative oncology retreat, was developed to address these unmet supportive care needs.
This prospective, exploratory, single-center observational matched cohort study aims to evaluate the feasibility of conducting a clinical study alongside the retreat, including recruitment, retention, adherence, and completeness of data collection. Participants attending the cure stay are compared with a matched control group not participating in the retreat. Study procedures include systematic assessment of patient-reported outcomes, wearable-based physiological data, and biological samples. Measurements are performed longitudinally across six time points over six months.
Secondary exploratory aims include describing potential changes in symptoms, wellbeing, and stress-related biomarkers following the retreat, as well as differences between retreat participants and controls. Findings will inform the design of future randomized controlled trials evaluating integrative oncology interventions and contribute to improving supportive cancer care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Integrative Cure Stay Group | Participants attend a 7-day integrative oncology retreat including individualized consultations, complementary therapies, and group-based mind-body interventions. |
| |
| Matched Control Group | Participants receive usual oncology follow-up without attending the retreat. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Integrative Cure Stay | Behavioral | Participants attend a 7-day integrative oncology retreat including individualized consultations, complementary therapies, and group-based mind-body interventions |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of Study Conduct (Composite Outcome) | Feasibility of study conduct assessed as a composite outcome based on predefined feasibility criteria, including recruitment rate, retention rate, adherence to study procedures, completeness of data collection, and logistical/operational feasibility. Overall feasibility will be determined by whether predefined thresholds for these criteria are met. | Baseline to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Life (EQ-5D-5L) | Change in health-related quality of life measured using the EQ-5D-5L questionnaire. EQ-5D-5L scoring involves combining responses from 5 dimensions (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression) into a 5-digit profile with values ranging from 11111 (best possible health state) to 55555 (worst possible health state). A separate EQ Visual Analog Scale (VAS) provides a subjective "health today" score (0-100). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Breast and gynecological cancer survivors who have completed primary treatment (surgery ± chemotherapy ± radiotherapy) and continue to experience long-term physical or psychological symptoms.
A matched control group consists of similar patients not attending the integrative cure stay program.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Isabell Ge, MD | Contact | +41 61 32 85885 | Isabellxiang.ge@usb.ch |
| Name | Affiliation | Role |
|---|---|---|
| Viola Heinzelmann-Schwarz, Prof. MD | University Hospital of Basel | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Basel | Recruiting | Basel | 4031 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001943 | Breast Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001941 | Breast Diseases |
| D012871 | Skin Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Serum
| Matched Control Group | Other | Participants receive usual oncology follow-up without attending the retreat |
|
| Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Quality of Life (VAS) | The EQ Visual Analog Scale (VAS) provides a subjective "health today" score (0-100). | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Psychological Distress (Distress Thermometer) | Change in psychological distress assessed using the Distress Thermometer, a valid and reliable measure developed by the National Comprehensive Cancer Network for screening psychological distress in cancer patients. The German version was adapted by Mehnert et al. A score of 5 or higher at the visual analogue scale. The score ranges from 0-10 while 10 indicates a higher stress level. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Perceived Stress (PSS-10) | Change in perceived stress levels measured with the 10-item Perceived Stress Scale. PSS-10 measures the degree to which life has been perceived as unpredictable, uncontrollable und overloading over the last month. The responses are rated on a 5-point rating scale with a total score ranging from 0-40 while a higher total score indicating greater stress. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Anxiety and Depression (HADS) | Change in anxiety and depression symptoms measured by the Hospital Anxiety and Depression Scale. The scale consists of 14 questions, with each question being assigned a value from 0 to 3. The total score can range from 0 to 21. Scores of 8-10 are considered borderline, 11-15 moderate, and 16 or higher severe anxiety or depression. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Resilience (CD-RISC-10) | Change in psychological resilience measured using the CD-RISC-10 questionnaire. It is the shortened version of a 25-items questionnaire which evaluates the patient's ability to bounce back when diagnosed with a disease. The responses are rated on a 5-point rating scale with the total score ranged from 0-40 while a higher total score indicating greater resilience. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Therapy Adherence | Change in adherence to ongoing maintenance therapies assessed via routine visit documentation and follow-up questionnaires. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Physiological Measures: HRV | Change in heart rate variability using a wearable device. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Physiological Measures (Pulse) | Change in pulse measured using a wearable device. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Physiological Measures (physical activity) | Change of daily physical activity is evaluated by the number of steps using a wearable device. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Salivary Cortisol | Change in diurnal cortisol levels (awakening, +30 min, +1 h, +6 h, +14 h) measured by LC-MS/MS. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Salivary Alpha-Amylase (sAA) | Change in salivary alpha-amylase activity as a biomarker of sympathetic activation. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Serum BDNF | Change in serum brain-derived neurotrophic factor levels measured via ELISA. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Microbiome Composition | Exploratory changes in gut, oral, and urinary microbiome diversity and composition assessed by 16S rRNA sequencing. | Baseline, pre-retreat, last day of retreat, 2 weeks, 1 month, 3 months, 6 months. |
| Subjective Evaluation of the Cure Stay | Participants' satisfaction and perceived benefit of the integrative cure stay is assessed by the questionnaire "personal evaluation of the cure stay". Scores ranges from 0-24 while higher scores indicate higher satisfaction. | Daily from day 3 to day 7 of the cure stay |
| D017437 |
| Skin and Connective Tissue Diseases |